Medical Xpress26d
Scientists develop new natural killer cell strategy to target HIV
cells to target and kill the HIV-positive cells that allow the virus to persist. Wistar scientists have labeled this new approach "NuKES": Natural Killer Enhancement Strategy. NK cells are unlike ...
EurekAlert!27d
Scientists at The Wistar Institute’s HIV Cure and Viral Diseases Center develop new natural killer cell strategy to target HIV
cells to target and kill the HIV-positive cells that allow the virus to persist. Wistar scientists have labeled this this new approach “NuKES”: Natural Killer Enhancement Strategy. NK cells ...
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success
The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
PipelineReview.com3d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...
Harnessing Gravity To Create a Low-Cost Device for Rapid Cell Analysis
An AI-enabled device could make flow cytometry affordable and accessible, reports a new study from Rice University.
College of Natural Sciences5d
Top Prize Image for Visualizing Science Shows a Logistic Map’s Chaotic Portion
The college’s Visualizing Science competition finalists include the winning image of a Logistic Map’s Chaotic Portion by an ...